Pilot study finds adiposity impairs femur strength and geometry while leaving bone mineral density unchanged, highlighting limits of standard fracture risk assessment.
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...